Allegra-D Joins ‘Common Cold’ Club In OTC Antihistamine Market

Allegra-D has competed in the OTC antihistamine space without including “relief of nasal congestion due to the common cold” in its indications since its 2011 launch through Sanofi’s Chattem business.

Allegra-D no longer is on the outside looking in at the OTC pseudoephedrine-containing antihistamine competition as FDA approves adding “relief of nasal congestion due to the common cold” to the Sanofi product label.

While Claritin-D, Zyrtec-D and generic versions of those brands have included the indication on labels since FDA approved each product,...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from United States

More from North America